Clinical Trials Directory

Trials / Unknown

UnknownNCT00999505

Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Hospital de Clinicas de Porto Alegre · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.

Conditions

Interventions

TypeNameDescription
DRUGAmantadineAmantadine 200mg twice a day over 12 weeks
DRUGPlaceboPlacebo capsules twice a day over 12 weeks

Timeline

Start date
2010-05-01
Primary completion
2011-09-01
Completion
2011-09-01
First posted
2009-10-21
Last updated
2011-02-16

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT00999505. Inclusion in this directory is not an endorsement.

Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia (NCT00999505) · Clinical Trials Directory